Adicet Bio, Inc.
- Open
- 8.76
- Day high
- 8.96
- Day low
- 8.67
- Prev close
- 8.55
- Volume
- 120K
- Mkt cap
- $84M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 0.6
- P/S
- —
- Yield
- —
- Per share
- —
Adicet Bio, Inc. (ACET) is a Healthcare company listed on NASDAQ. The stock is down 19% over the past year.
Adicet Bio, Inc. (ACET) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
ACET earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 13, 2026 | $-2.93 | $-1.88 | +35.8% | — | — |
| Mar 12, 2026 | $-2.91 | $-2.94 | -1.0% | — | — |
| Nov 5, 2025 | $-4.16 | $-4.64 | -11.5% | — | — |
| Aug 7, 2025 | $-5.12 | $-5.44 | -6.3% | — | — |
| Mar 6, 2025 | $-5.92 | $-5.12 | +13.5% | — | — |
| May 14, 2024 | $-5.60 | $-5.60 | +0.0% | — | — |
| Mar 19, 2024 | $-11.52 | $-11.04 | +4.2% | — | — |
| Mar 15, 2023 | $-8.96 | $-11.52 | -28.6% | — | — |
| Aug 10, 2022 | $-7.20 | $-8.96 | -24.4% | — | — |
| May 12, 2022 | $-1.12 | $1.60 | +242.9% | $25M | +73.6% |
| Mar 15, 2022 | $-7.04 | $-7.52 | -6.8% | $5M | +31.3% |
| Nov 10, 2021 | $-6.08 | $-7.04 | -15.8% | $3M | +18.8% |
ACET insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 23, 2026 | Klickstein Lloyddirector | Grant | 4,200 | $8.10 |
| Jun 23, 2026 | Peng Katiedirector | Grant | 4,200 | $8.10 |
| Jun 23, 2026 | Aftab Blakeofficer: Chief Scientific Officer | Grant | 55,000 | $8.10 |
| Jun 23, 2026 | Schor Chendirector, officer: President & CEO | Grant | 55,000 | $8.10 |
| Jun 23, 2026 | Sinclair Andrewdirector | Grant | 4,200 | $8.10 |
| Jun 23, 2026 | DUBIN STEVEdirector | Grant | 4,200 | $8.10 |
| Jun 23, 2026 | Grissinger Michaeldirector | Grant | 4,200 | $8.10 |
| Jun 23, 2026 | Chodakewitz Jeffreydirector | Grant | 4,200 | $8.10 |
| Apr 13, 2026 | RA CAPITAL MANAGEMENT, L.P.10 percent owner | Buy | 74,751 | $7.27 |
| Apr 13, 2026 | RA CAPITAL MANAGEMENT, L.P.10 percent owner | Buy | 74,577 | $7.04 |
| Apr 13, 2026 | RA CAPITAL MANAGEMENT, L.P.10 percent owner | Buy | 74,268 | $7.21 |
| Apr 9, 2026 | ORBIMED ADVISORS LLC10 percent owner | Sell | 40,416 | $6.52 |
| Apr 9, 2026 | ORBIMED ADVISORS LLC10 percent owner | Sell | 32,523 | $6.29 |
| Apr 9, 2026 | ORBIMED ADVISORS LLC10 percent owner | Sell | 29,319 | $6.53 |
| Apr 9, 2026 | ORBIMED ADVISORS LLC10 percent owner | Sell | 2,400 | $6.38 |
Source: ACET SEC Form 4 filings, latest Jun 23, 2026. For informational purposes only — not investment advice.
See the full ACET insider & 13F page →Adicet Bio, Inc. company profile
Overview
Adicet Bio, Inc. (NASDAQ:ACET) is a clinical-stage biotechnology company founded in 2014 and based in Boston, Massachusetts. The company went public in January 2018 and specializes in developing innovative cancer immunotherapies using genetically engineered immune cells. Adicet focuses specifically on gamma delta T cell therapies, representing a novel approach in the rapidly evolving field of cellular immunotherapy for treating various cancers and potentially other diseases.
Business
Adicet Bio operates in the biotechnology sector, specifically within the cellular immunotherapy segment of cancer treatment. The company's core focus is developing allogeneic gamma delta T cell therapies, which represents a cutting-edge approach to cancer treatment that harnesses the body's immune system to fight tumors. To understand Adicet's technology, it's important to know that T cells are a type of white blood cell that plays a crucial role in the immune system's ability to recognize and destroy abnormal cells, including cancer cells. Gamma delta T cells are a specialized subset of T cells that can naturally recognize and kill cancer cells without needing prior exposure to specific antigens. Unlike conventional T cell therapies that are often derived from a patient's own cells (autologous), Adicet's approach uses allogeneic cells, meaning they come from healthy donors and can potentially be used as "off-the-shelf" treatments for multiple patients. The company enhances these gamma delta T cells through genetic engineering, incorporating chimeric antigen receptors (CARs) and T cell receptor-like antibodies. These modifications are designed to improve the cells' ability to selectively target tumor cells, enhance their persistence in the patient's body, and facilitate both innate and adaptive immune responses against cancer. Adicet's pipeline consists of two main programs: 1. ADI-001: The company's lead product candidate, currently in Phase I clinical trials for treating non-Hodgkin's lymphoma, a type of blood cancer that affects the lymphatic system. 2. ADI-002: A second-generation therapy in preclinical development targeting various solid tumors, which represent cancers that form solid masses in organs and tissues rather than blood-based cancers. The company operates as a single business segment focused entirely on research and development of these gamma delta T cell therapies, with no current commercial revenue from product sales.
Revenue model
As a clinical-stage biotechnology company, Adicet Bio currently generates no revenue from product sales, as evidenced by zero revenue reported in recent quarters. The company's business model is typical of early-stage biotech firms, relying primarily on equity financing and potential future licensing partnerships to fund operations until products reach commercialization. Historically, the company did report $25 million in revenue in 2022, likely from research collaborations, licensing agreements, or milestone payments from pharmaceutical partners. However, this revenue stream appears to have concluded, and the company is now operating purely as a development-stage entity. Once Adicet's therapies reach market approval, the company would likely generate revenue through several potential models: direct product sales to hospitals and treatment centers, licensing agreements with larger pharmaceutical companies for commercialization rights, or milestone and royalty payments from strategic partnerships. Given the specialized nature of cellular immunotherapies, the paying customers would primarily be cancer treatment centers, hospitals, and healthcare systems that administer these complex therapies. Several factors could significantly impact Adicet's future profitability margins. Manufacturing complexity represents a major cost consideration, as producing genetically engineered cellular therapies requires sophisticated facilities and quality control processes. Regulatory approval timelines directly affect when revenue generation can begin, while competition from other immunotherapy approaches, including CAR-T therapies from established pharmaceutical companies, could pressure pricing power. Clinical trial success rates will determine whether the substantial R&D investments yield marketable products. Additionally, reimbursement policies from insurance providers and healthcare systems will significantly influence market access and pricing for these expensive therapies. The company's allogeneic approach could provide cost advantages over autologous therapies by enabling larger-scale manufacturing, but this benefit depends on successfully demonstrating safety and efficacy in clinical trials.
Competitive moat
Adicet Bio's competitive moat is relatively narrow and primarily based on its specialized expertise in gamma delta T cell engineering and early-mover advantage in this specific therapeutic approach. The company's intellectual property portfolio around its proprietary methods for enhancing gamma delta T cells provides some protection, but biotechnology patents can often be circumvented through alternative approaches. The most significant potential moat lies in the allogeneic nature of Adicet's approach. If successful, off-the-shelf gamma delta T cell therapies could offer substantial advantages over current autologous CAR-T therapies, which require individualized manufacturing for each patient, resulting in higher costs and longer treatment delays. This manufacturing efficiency could create a competitive advantage in terms of cost structure and treatment accessibility. However, the moat faces substantial challenges. The cellular immunotherapy field is highly competitive, with numerous well-funded competitors including large pharmaceutical companies like Gilead, Bristol Myers Squibb, and Novartis, all of whom have significantly more resources and established market presence. These companies are also exploring allogeneic approaches and have proven capabilities in bringing cellular therapies to market. The regulatory pathway for cellular immunotherapies remains complex and uncertain, and clinical trial failures could quickly erode any competitive advantages. Additionally, the underlying science of gamma delta T cell therapy, while promising, is not proprietary to Adicet, meaning other companies can pursue similar approaches with potentially superior execution or resources. Overall, Adicet's moat is relatively weak and depends heavily on successful clinical execution and the ability to demonstrate clear advantages over existing therapies. The company's survival and competitive position will largely depend on clinical trial outcomes and its ability to secure strategic partnerships with larger pharmaceutical companies that can provide the resources needed for late-stage development and commercialization.
Risks & safety
Adicet Bio presents significant financial risks typical of clinical-stage biotechnology companies, with limited margin of safety for investors. • Cash position and burn rate: The company held $28.1 million in cash as of Q1 2025, down from $56.5 million in Q4 2024, indicating rapid cash depletion. With quarterly cash burn of approximately $25-30 million, the company has less than one year of runway at current spending levels. • Debt and solvency: Low debt levels with debt-to-equity ratio of 0.10, indicating minimal leverage risk. However, the company faces immediate solvency concerns given the cash burn rate and lack of revenue. • Valuation metrics: Trading at 0.43x price-to-book ratio suggests the stock is trading below book value. However, negative earnings make traditional valuation metrics less meaningful. The enterprise value to EBITDA ratio is negative due to losses. • Operating losses: Consistent quarterly losses of $28-30 million with negative EBITDA of similar magnitude indicate no path to profitability in the near term without successful clinical outcomes. • Liquidity concerns: Strong current ratio of 9.3x indicates good short-term liquidity relative to current liabilities, but this is misleading given the rapid cash consumption rate. • Market capitalization: At approximately $63 million market cap, the company is trading at a significant discount to its cash and asset base, suggesting either deep value or market skepticism about prospects. The primary risk is the need for additional financing within the next 6-12 months, likely through dilutive equity raises or strategic partnerships.
Recent development
Based on the available financial data, Adicet Bio has maintained consistent focus on advancing its gamma delta T cell therapy programs over recent years. The company's primary strategic development has been progressing ADI-001 through Phase I clinical trials for non-Hodgkin's lymphoma treatment, representing a significant milestone in validating their allogeneic gamma delta T cell approach. The company has also been advancing ADI-002 through preclinical development for solid tumor applications, expanding their potential market opportunity beyond blood cancers. This represents a strategic broadening of their therapeutic pipeline to address larger cancer markets. A notable shift occurred between 2022 and 2023, when the company transitioned from generating collaboration revenue ($25 million in 2022) to operating purely as a development-stage entity with zero revenue in subsequent periods. This suggests either the conclusion of previous partnership agreements or a strategic pivot toward independent development of their core programs. The company has been managing a controlled cash burn strategy, maintaining quarterly operating expenses in the $25-30 million range while advancing clinical programs. However, the declining cash position from over $200 million in mid-2024 to approximately $28 million by Q1 2025 indicates the company is approaching a critical inflection point where additional financing or strategic partnerships will be necessary to continue operations. Recent development efforts appear focused on generating clinical data from the ADI-001 program that could attract strategic partners or support future financing rounds, as the company lacks the resources for independent late-stage development and commercialization of cellular therapies.
ACET company profile · for informational purposes only — not investment advice.
Track ACET with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free